NeoGenomics Company Leadership
| NEO Stock | USD 6.24 0.48 7.14% |
NeoGenomics employs about 2.2 K people. The company is managed by 26 executives with a total tenure of roughly 21 years, averaging almost 0.0 years of service per executive, having 84.62 employees per reported executive. Analysis of NeoGenomics' management performance can provide insight into the firm performance.
| Kathryn McKenzie President Principal Accounting Officer, Vice President - Finance |
| William Bonello President Vice President of Strategy - Corporate Development and Investor Relations |
NeoGenomics | Build AI portfolio with NeoGenomics Stock |
NeoGenomics' latest congressional trading
Congressional trading in companies like NeoGenomics, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in NeoGenomics by those in governmental positions are based on the same information available to the general public.
| 2025-06-06 | Representative Gilbert Cisneros | Acquired Under $15K | Verify |
NeoGenomics Management Team Effectiveness
The company has Return on Asset of (0.0275) % which means that on every $100 spent on assets, it lost $0.0275. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0857) %, meaning that it generated no profit with money invested by stockholders. NeoGenomics' management efficiency ratios could be used to measure how well NeoGenomics manages its routine affairs as well as how well it operates its assets and liabilities.NeoGenomics Workforce Comparison
NeoGenomics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 26,343. NeoGenomics holds roughly 2,200 in number of employees claiming about 8% of equities under Health Care industry.
The company has Net Profit Margin of (0.12) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.17) %, which entails that for every $100 of revenue, it lost $0.17. NeoGenomics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NeoGenomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on NeoGenomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, NeoGenomics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Floegel Elizabeth over three weeks ago Acquisition by Floegel Elizabeth of 23077 shares of NeoGenomics subject to Rule 16b-3 | ||
Green Marjorie C over three weeks ago Insider Trading | ||
Perez David Brian over a month ago Disposition of 12254 shares by Perez David Brian of NeoGenomics subject to Rule 16b-3 | ||
Warren Stone over two months ago Acquisition by Warren Stone of 5700 shares of NeoGenomics at 8.578 subject to Rule 16b-3 | ||
Warren Stone over two months ago Disposition of 9613 shares by Warren Stone of NeoGenomics subject to Rule 16b-3 | ||
Smith Christopher M over three months ago Disposition of 57413 shares by Smith Christopher M of NeoGenomics subject to Rule 16b-3 | ||
Sherman Jeffrey Scott over three months ago Acquisition by Sherman Jeffrey Scott of 126476 shares of NeoGenomics subject to Rule 16b-3 | ||
Williams Felicia over three months ago Acquisition by Williams Felicia of 5430 shares of NeoGenomics at 13.59 subject to Rule 16b-3 |
NeoGenomics Notable Stakeholders
A NeoGenomics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NeoGenomics often face trade-offs trying to please all of them. NeoGenomics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NeoGenomics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Anthony Zook | CEO Director | Profile | |
| Vishal Sikri | President Diagnostics | Profile | |
| Kathryn McKenzie | Principal Accounting Officer, Vice President - Finance | Profile | |
| William Bonello | Vice President of Strategy - Corporate Development and Investor Relations | Profile | |
| Warren Stone | President Division | Profile | |
| JD Esq | President Informatics | Profile | |
| Fernando LpezDaz | Director Science | Profile | |
| Nathan MD | Vice Services | Profile | |
| George Cardoza | Pres Operations | Profile | |
| Gary Passman | Chief Officer | Profile | |
| Alicia Olivo | General Development | Profile | |
| Andrew Lukowiak | Chief Officer | Profile | |
| Cynthia Dieter | Chief Officer | Profile | |
| Christopher BSc | CEO Director | Profile | |
| Charlie Eidson | Director Devel | Profile | |
| Hutan JD | Chief Officer | Profile | |
| Beth Eastland | Senior Sales | Profile | |
| John Mooney | Chief Officer | Profile | |
| Greg Sparks | Chief Officer | Profile | |
| Facmg MBA | Pres Officer | Profile | |
| Kareem Saad | Head Transformation | Profile | |
| Ali Olivio | Gen Sec | Profile | |
| Kendra Sweeney | Vice Communications | Profile | |
| Derek MD | Chief Officer | Profile | |
| Gregory Aunan | Senior Officer | Profile | |
| Jeffrey MBA | Chief Officer | Profile |
About NeoGenomics Management Performance
The success or failure of an entity such as NeoGenomics often depends on how effective the management is. NeoGenomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NeoGenomics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NeoGenomics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Neogenomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people.
NeoGenomics Workforce Analysis
Traditionally, organizations such as NeoGenomics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NeoGenomics within its industry.NeoGenomics Manpower Efficiency
Return on NeoGenomics Manpower
| Revenue Per Employee | 300.3K | |
| Revenue Per Executive | 25.4M | |
| Net Loss Per Employee | 35.8K | |
| Net Loss Per Executive | 3M | |
| Working Capital Per Employee | 134K | |
| Working Capital Per Executive | 11.3M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.